The US Federal Trade Commission wants to understand the current state of play as it considers whether prescription drug contract and purchasing practices by pharmacy benefit managers and group purchasing organizations (GPOs) are driving anti-competitive behavior in the health care system.
The agency convened panels of experts at a Nov. 8 workshop to explain how the intermediaries work in the drug supply chain. Discussions explored whether the current rebate demands by PBMs and the fact that GPO fees are paid by manufacturers may be driving up costs for patients and payers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?